OverviewSuggest Edit

Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
TypePublic
Founded1996
HQDublin, IE
Websitetheravance.com
Culture scoreB-

Latest Updates

Employees (est.) (Mar 2019)363(+7%)
Job Openings18
Revenue (FY, 2018)$60.4 M(+293%)
Share Price (Mar 2020)$21.1 (-9%)

Key People/Management at Theravance Biopharma

Rick Winningham

Rick Winningham

Director, CEO
Eran Broshy

Eran Broshy

Director
Dennis O. Driver

Dennis O. Driver

Senior Vice President, Human Resources, Organizational and Leadership Development
Gary Barrera

Gary Barrera

Director
Robert V. Gunderson

Robert V. Gunderson

Director
Rhonda F. Farnum

Rhonda F. Farnum

Vice President, Sales & Marketing
Show more

Theravance Biopharma Office Locations

Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, US
901 Gateway Boulevard
Show all (2)

Theravance Biopharma Financials and Metrics

Theravance Biopharma Revenue

Embed Graph
View revenue for all periods
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
USD

Revenue (FY, 2018)

60.4m

Revenue growth (FY, 2017 - FY, 2018), %

292.4%

Gross profit (FY, 2018)

59.7m

Gross profit margin (FY, 2018), %

98.8%

Net income (FY, 2018)

(215.5m)

EBIT (FY, 2018)

(238.8m)

Market capitalization (27-Mar-2020)

1.3b

Closing stock price (27-Mar-2020)

21.1

Cash (31-Dec-2018)

378.0m

EV

1.2b
Theravance Biopharma's current market capitalization is $1.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

48.6m15.4m60.4m

Revenue growth, %

(68%)292%

Cost of goods sold

2.9m6.0m715.0k

Gross profit

45.8m9.4m59.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

18.4m5.5m19.1m3.1m3.5m4.3m8.3m23.5m12.8m

Cost of goods sold

778.0k638.0k332.0k565.0k1.4m985.0k1.4m705.0k

Gross profit

17.6m4.8m18.7m2.5m2.1m3.3m22.0m12.1m

Gross profit Margin, %

96%88%98%82%61%77%94%95%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

344.7m89.0m378.0m

Accounts Receivable

646.0k2.3m620.0k

Inventories

12.2m16.8m

Current Assets

528.5m378.7m532.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

128.8m148.4m86.6m169.9m139.6m91.3m125.8m103.9m101.2m

Accounts Receivable

1.5m1.9m873.0k1.2m1.3m1.6m2.0m3.4m3.0m

Inventories

9.4m9.8m12.5m13.2m12.1m15.3m17.2m17.9m17.9m

Current Assets

238.8m303.1m274.0m421.5m384.9m367.1m446.8m386.7m332.6m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(190.7m)(285.4m)(215.5m)

Depreciation and Amortization

3.1m4.0m3.2m

Inventories

(3.2m)(7.3m)(1.6m)

Accounts Payable

(16.4m)3.8m3.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(42.1m)(89.4m)(123.3m)(65.3m)(131.6m)(198.5m)(65.1m)(105.9m)(165.3m)

Depreciation and Amortization

699.0k1.2m1.9m1.1m2.1m3.0m900.0k1.7m2.3m

Inventories

134.0k157.0k(1.8m)140.0k(497.0k)(3.0m)(371.0k)(351.0k)(552.0k)

Accounts Payable

(9.4m)(10.8m)(12.8m)2.0m4.8m3.5m(449.0k)(2.3m)(1.7m)
USDY, 2018

EV/EBIT

-4.9 x

EV/CFO

-10.4 x

Debt/Equity

-4.4 x

Debt/Assets

0.4 x

Financial Leverage

-10.9 x
Show all financial metrics

Theravance Biopharma Operating Metrics

FY, 2016FY, 2017FY, 2018Apr, 2019

Partners

6

Patents (Foreign)

1.68 k1.96 k1.67 k

Patents (US)

434 459 438
Show all operating metrics

Theravance Biopharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Theravance Biopharma Antibiotics IP
Theravance Biopharma Ireland Limited
Theravance Biopharma R&D
Theravance Biopharma R&D IP
Theravance Biopharma UK Limited
Theravance Biopharma US
Triple Royalty Sub LLC

Theravance Biopharma Revenue Breakdown

Embed Graph

Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other

Theravance Biopharma Online and Social Media Presence

Embed Graph

Theravance Biopharma Company Culture

  • Overall Culture

    B-

    75/100

  • CEO Rating

    A

    80/100

  • Compensation

    D

    54/100

Learn more on Comparably

Theravance Biopharma News and Updates

Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the...

Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK)...

Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial...

Theravance Biopharma and Mylan Expand YUPELRI (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories.read more

Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019

DUBLIN, Ireland, May 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported data from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473, in an oral presentation at Digestive...

Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety...
Show more

Theravance Biopharma Blogs

Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes

Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes Content Import Mon, 03/02/2020 - 07:01 Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes March 2, 2020 at 7:00 AM EST Th…

Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update Content Import Mon, 02/24/2020 - 16:06 Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update Febr…

Theravance Biopharma Announces Presentations at Upcoming Investor Conferences

Theravance Biopharma Announces Presentations at Upcoming Investor Conferences Content Import Tue, 02/18/2020 - 07:01 Theravance Biopharma Announces Presentations at Upcoming Investor Conferences February 18, 2020 at 7:00 AM EST This release is a backfill from …

Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

DUBLIN , Feb. 13, 2020 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial and operating

Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares

Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares Content Import Mon, 02/10/2020 - 16:01 Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares February 10, 2020 at 4:01 PM EST This release is a backfill from a News…

Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference Content Import Tue, 01/07/2020 - 16:49 Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference January 7, 2020 at 4:48 PM EST …
Show more

Theravance Biopharma Frequently Asked Questions

  • When was Theravance Biopharma founded?

    Theravance Biopharma was founded in 1996.

  • Who are Theravance Biopharma key executives?

    Theravance Biopharma's key executives are Rick Winningham, Eran Broshy and Dennis O. Driver.

  • How many employees does Theravance Biopharma have?

    Theravance Biopharma has 363 employees.

  • What is Theravance Biopharma revenue?

    Latest Theravance Biopharma annual revenue is $60.4 m.

  • What is Theravance Biopharma revenue per employee?

    Latest Theravance Biopharma revenue per employee is $166.3 k.

  • Who are Theravance Biopharma competitors?

    Competitors of Theravance Biopharma include Prothena, Inflazome and Aimmune Therapeutics.

  • Where is Theravance Biopharma headquarters?

    Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.

  • Where are Theravance Biopharma offices?

    Theravance Biopharma has offices in Dublin and San Francisco.

  • How many offices does Theravance Biopharma have?

    Theravance Biopharma has 2 offices.